KSKatharine Alison Smith

Katharine Alison Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katharine Alison Smith has a total of 190 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Context-dependent effects of ketamine on emotional evidence integration

    by Miruna Rascu, Jan Grohn, Sara Costi, Caroline Zangani, Samuel Agyapong, Katharine A. Smith, Philip J. Cowen, Laurence T. Hunt, Miriam C. Klein-Flügge, Lilian A. Weber

    Understanding others’ emotions requires continuously integrating noisy affective information as emotional states change over time. Research on emotion processing, however, has thus far focused on static environments or discrete events. Here, we developed a continuous emotional evidence integration task in which participants had to track the average emotional state in a rapidly changing sequence of faces under different levels of environmental volatility. This allowed us to examine emotion integration in changing environments. In online (n=92) and in-person (n=29) cohorts, participants integrated emotional information over longer timescales in stable environments while relying more strongly on recent evidence under volatility, consistent with principles established in perceptual decision-making. We further examined whether this process was modulated by ketamine, an NMDA receptor antagonist associated with evidence integration in the perceptual domain. We conducted a double-blind, placebo-controlled, within-subject study and probed emotion integration during the post-acute period, approximately 1.5 hours after the infusion. Ketamine modulated the temporal weighting of emotional evidence, shifting the balance between recent and past information depending on environmental volatility. Together, these findings show that emotional evidence integration dynamically adapts to the statistical structure of the environment and that ketamine can further modulate this process, which may have relevance for affective disorders.

  • Open Access

    The GALENOS approach to triangulating evidence: a structured approach for integrating information from human and animal studies

    by Thomy Tonia, Julian P.T. Higgins, Virginia Chiocchia, James Downs, Emily Wheeler, Jennifer Potts, Katharine A. Smith, Malcolm Macleod, Gin S. Malhi, Andrea Cipriani, et al.

    Background: Most decision-making research involves collating multiple types of evidence, and such integration should be a core component of investigative practice in science. Triangulation is one formal approach that has proven effective, typically drawing on sources of evidence with different biases. However, there remains no standardised method for its implementation and no clear guidance on how to apply triangulation in research contexts—particularly when synthesising evidence across human and animal data. Methods: GALENOS (Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis) has introduced GATE (GALENOS Approach to Triangulating Evidence), a multifaceted framework for such triangulation. To further develop GATE, we here systematically searched the literature for work describing triangulation processes for human and animal data. Results: As a key component of GATE, we provide conceptual details and practical guidance on how to prepare, organise, conduct, and follow up on triangulation meetings. Conclusions: Based on findings from this literature and our experience with GATE, we updated our approach.


  • Open Access

    Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin

    by Katharine A. Smith, Edward Harcourt, Andrea Cipriani

    Summary: Psychedelics are increasingly described as a new therapeutic approach in a variety of mental disorders including depression. Oral psychedelics such as psilocybin have an acute effect evolving over 6–8 h and are generally given in combination with psychological support. There is debate on the exact role of this support and how and by whom it should be delivered. This has significant implications for real-world implementation in health services post-licensing. In this feature, we discuss these issues and outline a model for psychological support delivery in publicly funded health services such as the National Health Service. We also suggest further research to explore the exact role of support in psilocybin treatment and identify the essential elements to direct service plans for clinical implementation. These steps are important: over recent decades, there have been few new treatments for depression, moreover, psychedelic drugs are appealing to patients, and accumulating data suggest that their efficacy may be long-lasting. However, realistic plans for implementation must be based on high-quality evidence and the needs of the whole patient population. This will ensure that these treatments, if licensed, are available not only for those able to pay but to all on an equitable basis.


  • Open Access

    AI assisted triage of UK patients in mental health care services: a qualitative focus group study of patients’ attitudes

    by Katharine A. Smith, Julia Hamer-Hunt, Andrey Kormilitzin, Helen Page, Dan W. Joyce, Andrea Cipriani, Jane Grieve, Oana Colta, Jim McMahon, Lindsey Hammil-Evans, et al.

    Background: The referral process between healthcare services can be complex, especially in psychiatry, leading to significant delays and ‘hidden waiting lists’. Digital approaches may be helpful. The CHRONOSIG (CHRONOlogical SIGnature) project aims to improve the referral and triage process by applying machine learning (ML) technology to information in electronic health records. We used a focus group methodology to ascertain the views of patients and participants on using CHRONOSIG and similar digital approaches to support decision making in triaging referrals in difficult to treat depression, and the potential benefits and disadvantages of such an approach. Methods: A lived experience participant focus group ( N = 16) was held on 25th September, 2024, with a lived experience chair. Participants were recruited by convenience sampling. Data were analysed thematically and managed using the Framework method, with double coding of transcripts, and reported using COREQ guidelines. Results: Main themes from the analysis were: (i) the complexity of mental health needs assessments; (ii) challenges in the current mental health system; (iii) general challenges of using a computer/artificial intelligence based tool for risk prediction and clinical decision support; (iv) differences and similarities in using a computer-based prediction tool in mental health vs. in physical health; (v) possible benefits and harms; (vi) factors to consider in the future. Conclusions: Patient engagement is a key challenge for digital tools in mental health, but previous studies in digital decision support tools have focussed on clinician feedback. In this study we ascertained the views of lived experience participants in mental healthcare triage and referral in difficult to treat depression. Participants identified delays, errors and confusion in the referral process and expressed positive views on the ability of the CHRONOSIG tool to help to improve waiting times and time spent between services, particularly when used as an addition to a high-quality clinical consultation. In many countries there are shortfalls in mental health care provision with increasing waits in both recorded and unrecorded waiting lists. This study supports a potential route to improve these processes; by more accurately and efficiently identifying the needs of patients and matching these to suitable services and research opportunities.


  • Open Access

    Beyond counting clicks: rethinking engagement in digital mental health

    by Andrea Cipriani, Thomas Ward, Sinéad Lambe, Edoardo G. Ostinelli, Charlotte Blease, Thomas Gant, Stefan M. Gold, Emily A. Holmes, Ivana Paccoud, Anastasia Vinnikova, et al.

    Summary: User engagement remains a challenge in digital mental health. This editorial reconsiders engagement as a process rather than an outcome, introducing a four-step model to define, measure and link engagement to outcomes. The approach promotes standardisation, interpretability and scalability, advancing the science and implementation of digital health interventions.


  • Open Access

    GALENOS approach to triangulating evidence (GATE): transforming the landscape of psychiatric research

    by Katharine A. Smith, James Downs, Emma S. J. Robinson, Gin S. Malhi, Jennifer Potts, Thomy Tonia, Georgia Salanti, Andrea Cipriani

    Summary: There is an urgent need for better evidence-based interventions in mental health. High-quality randomised controlled trials in humans are often lacking, especially when dealing with complex situations or novel therapeutic targets. Other potentially useful data may be available, such as from early-phase trials, observational or mechanistic studies or animal experiments. Triangulation offers an opportunity to consider a wider variety of evidence together to prioritise future research directions, and ultimately to inform clinical decisions. Here we describe GATE (the GALENOS Approach to Triangulating Evidence). This is the methodology of triangulation, co-produced with people with lived experience, and applied as an integral part of the GALENOS project (Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis; https://www.galenos.org.uk/ ). We outline the considerations of triangulation in psychiatry and our experience to date in assessing animal and human data together, using triangulation to prioritise future research directions. With GATE at its core, GALENOS not only enables novel insights to emerge, but points us towards a future of collaborative research better equipped to examine the most pressing questions in mental health.


  • Top Cited Papers
    Open Access

    Engagement and attrition in digital mental health: current challenges and potential solutions

    by Katharine A. Smith, Thomas Ward, Sinéad Lambe, Edoardo G. Ostinelli, Charlotte Blease, Thomas Gant, Stefan M. Gold, Emily A. Holmes, Ivana Paccoud, Anastasia Vinnikova, et al.

    In digital mental health engagement rates are consistently low, which may limit its effects. Using an international multidisciplinary consensus method, including lived experience expertise and a systematic review, we identified three key challenges: (i) lack of agreed metrics for engagement; (ii) lack of evidence on how better engagement improves outcomes; (iii) lack of standards for user involvement. Three potential solutions encompassed: (i) standardisation of frameworks for reporting engagement metrics and optimal doses of digital tools, (ii) measuring engagement with more precise reporting of outcomes, including potential harms; (iii) defining standards of user involvement (including appropriate diversity, and clinician as well as user input). Digital interventions have real potential in meeting the shortfall in service provision for mental health, but this will require focus on high quality research studies of the underlying mechanisms of engagement and optimal outcomes. Our findings identify and highlight the next best steps in this process.


  • Open Access

    Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis

    by Katharine A. Smith, Niall Boyce, Astrid Chevance, Virginia Chiocchia, Christoph U. Correll, Kim Donoghue, Nikita Ghodke, Tatenda Kambeu, Gin S. Malhi, Malcolm Macleod, et al.

    Background: Trace amine-associated receptor 1 (TAAR1) agonists offer a new approach, but there is uncertainty regarding their effects, exact mechanism of action and potential role in treating psychosis.Aims: To evaluate the available evidence on TAAR1 agonists in psychosis, using triangulation of the output of living systematic reviews (LSRs) of animal and human studies, and provide recommendations for future research prioritisation.Method: This study is part of GALENOS (Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis). In the triangulation process, a multidisciplinary group of experts, including those with lived experience, met and appraised the first co-produced living systematic reviews from GALENOS, on TAAR1 agonists.Results: The animal data suggested a potential antipsychotic effect, as TAAR1 agonists reduced locomotor activity induced by pro-psychotic drug treatment. Human studies showed few differences for ulotaront and ralmitaront compared with placebo in improving overall symptoms in adults with acute schizophrenia (four studies, n = 1291 participants, standardised mean difference (SMD) 0.15, 95% CI −0.05 to 0.34). Large placebo responses were seen in ulotaront phase three trials. Ralmitaront was less efficacious than risperidone (one study, n = 156 participants, SMD = −0.53, 95% CI −0.86 to −0.20). The side-effect profile of TAAR1 agonists was favourable compared with existing antipsychotics. Priorities for future studies included (a) using different animal models of psychosis with greater translational validity; (b) animal and human studies with wider outcomes including cognitive and affective symptoms and (c) mechanistic studies and investigations of other potential applications, such as adjunctive treatments and long-term outcomes. Recommendations for future iterations of the LSRs included (a) meta-analysis of individual human participant data, (b) including studies that used different methodologies and (c) assessing other disorders and symptoms.Conclusions: This co-produced, international triangulation examined the available evidence and developed recommendations for future research and clinical applications for TAAR1 agonists in psychosis. Broader challenges included difficulties in assessing the risk of bias, reproducibility, translation and interpretability of animal models to clinical outcomes, and a lack of individual and clinical characteristics in the human data. The research will inform a separate, independent prioritisation process, led by lived experience experts, to prioritise directions for future research.


  • Open Access

    Digital Mental Health for Schizophrenia and Other Severe Mental Illnesses: An International Consensus on Current Challenges and Potential Solutions

    by Katharine A Smith, Amy Hardy, Anastasia Vinnikova, Charlotte Blease, Lea Milligan, Diego Hidalgo-Mazzei, Sinéad Lambe, Lisa Marzano, Peter J Uhlhaas, Edoardo G Ostinelli, et al.

    Background: Digital approaches may be helpful in augmenting care to address unmet mental health needs, particularly for schizophrenia and severe mental illness (SMI). Objective: An international multidisciplinary group was convened to reach a consensus on the challenges and potential solutions regarding collecting data, delivering treatment, and the ethical challenges in digital mental health approaches for schizophrenia and SMI. Methods: The consensus development panel method was used, with an in-person meeting of 2 groups: the expert group and the panel. Membership was multidisciplinary including those with lived experience, with equal participation at all stages and coproduction of the consensus outputs and summary. Relevant literature was shared in advance of the meeting, and a systematic search of the recent literature on digital mental health interventions for schizophrenia and psychosis was completed to ensure that the panel was informed before the meeting with the expert group. Results: Four broad areas of challenge and proposed solutions were identified: (1) user involvement for real coproduction; (2) new approaches to methodology in digital mental health, including agreed standards, data sharing, measuring harms, prevention strategies, and mechanistic research; (3) regulation and funding issues; and (4) implementation in real-world settings (including multidisciplinary collaboration, training, augmenting existing service provision, and social and population-focused approaches). Examples are provided with more detail on human-centered research design, lived experience perspectives, and biomedical ethics in digital mental health approaches for SMI. Conclusions: The group agreed by consensus on a number of recommendations: (1) a new and improved approach to digital mental health research (with agreed reporting standards, data sharing, and shared protocols), (2) equal emphasis on social and population research as well as biological and psychological approaches, (3) meaningful collaborations across varied disciplines that have previously not worked closely together, (4) increased focus on the business model and product with planning and new funding structures across the whole development pathway, (5) increased focus and reporting on ethical issues and potential harms, and (6) organizational changes to allow for true communication and coproduction with those with lived experience of SMI. This study approach, combining an international expert meeting with patient and public involvement and engagement throughout the process, consensus methodology, discussion, and publication, is a helpful way to identify directions for future research and clinical implementation in rapidly evolving areas and can be combined with measurements of real-world clinical impact over time. Similar initiatives will be helpful in other areas of digital mental health and similarly fast-evolving fields to focus research and organizational change and effect improved real-world clinical implementation.